Emend is an anti-nausea medication owned by Merck. It contains aprepitant as its active ingredient and was first authorized for market use on March 26, 2003. It is available in capsule oral dosage forms.
Emend's generic is due for release after September 26, 2027. This is linked with the expiry date of its last patent, specifically patent number US8258132 titled 'Pharmaceutical composition of a tachykinin receptor antagonist.'
Emend is primarily used to prevent postoperative nausea and vomiting, and is also effective in preventing nausea and vomiting associated with chemotherapy treatment. Its active ingredient, aprepitant, is crucial in achieving these effects.
Emend holds a single patent, with the last one expiring on September 26, 2027 - this will set the stage for the release of Emend generic. Below are the details of the patent: